BACKGROUND: Recently, it has been postulated that long-term use of beta blockers might decrease the risk of certain types of cancer because of weakening of norepinephrine signaling. Previous studies on colorectal cancer (CRC) yielded inconsistent results, but lacked information on covariates. Thus, the authors investigated the association of beta blocker use and CRC risk in a large population-based case-control study (DACHS study). METHODS: Between 2003 and 2007, information on beta blocker use and potential confounders was collected by personal interviews for 1762 CRC cases and 1708 control individuals from Germany. The association of CRC risk and beta blocker use and subclasses of beta blockers was estimated by multiple logistic regression. In addition, site- and stage-specific analyses were performed. RESULTS: After adjustment for covariates, no association was observed with beta blocker use (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.86-1.29) or with duration of beta blocker use. Also, the analysis by subclasses of beta blockers (cardioselectivity) and active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol) or by CRC subsite showed no associations. In stage-specific analyses, long-term beta blocker use (6+ years) was associated with a significantly higher risk of stage IV CRC (OR, 2.02; 95% CI, 1.25-3.27). CONCLUSIONS: Our adjusted results do not support the hypothesis that beta blocker use is associated with decreased risk of CRC. In contrast, we found a positive association of long-term beta blocker use and risk of stage IV CRC. The latter result should be further evaluated in future studies.
BACKGROUND: Recently, it has been postulated that long-term use of beta blockers might decrease the risk of certain types of cancer because of weakening of norepinephrine signaling. Previous studies on colorectal cancer (CRC) yielded inconsistent results, but lacked information on covariates. Thus, the authors investigated the association of beta blocker use and CRC risk in a large population-based case-control study (DACHS study). METHODS: Between 2003 and 2007, information on beta blocker use and potential confounders was collected by personal interviews for 1762 CRC cases and 1708 control individuals from Germany. The association of CRC risk and beta blocker use and subclasses of beta blockers was estimated by multiple logistic regression. In addition, site- and stage-specific analyses were performed. RESULTS: After adjustment for covariates, no association was observed with beta blocker use (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.86-1.29) or with duration of beta blocker use. Also, the analysis by subclasses of beta blockers (cardioselectivity) and active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol) or by CRC subsite showed no associations. In stage-specific analyses, long-term beta blocker use (6+ years) was associated with a significantly higher risk of stage IV CRC (OR, 2.02; 95% CI, 1.25-3.27). CONCLUSIONS: Our adjusted results do not support the hypothesis that beta blocker use is associated with decreased risk of CRC. In contrast, we found a positive association of long-term beta blocker use and risk of stage IV CRC. The latter result should be further evaluated in future studies.
Authors: Phyo T Htoo; Til Stürmer; Michele Jonsson-Funk; Virginia Pate; Ross J Simpson; Jennifer L Lund Journal: Epidemiology Date: 2019-11 Impact factor: 4.822
Authors: Sarah Ouahoud; Rutger J Jacobs; Ludmilla L Kodach; Philip W Voorneveld; Lukas J A C Hawinkels; Nikki L Weil; Britt van Vliet; Ron M Herings; Lennart R A van der Burg; Tom van Wezel; Hans Morreau; Marije Slingerland; Esther Bastiaannet; Hein Putter; James C H Hardwick Journal: Br J Cancer Date: 2021-10-26 Impact factor: 7.640
Authors: Yin Zhang; Mingyang Song; Andrew T Chan; Jeffrey A Meyerhardt; Walter C Willett; Edward L Giovannucci Journal: Br J Cancer Date: 2022-09-22 Impact factor: 9.075
Authors: James Yarmolinsky; Virginia Díez-Obrero; Tom G Richardson; Marie Pigeyre; Jennifer Sjaarda; Guillaume Paré; Venexia M Walker; Emma E Vincent; Vanessa Y Tan; Mireia Obón-Santacana; Demetrius Albanes; Jochen Hampe; Andrea Gsur; Heather Hampel; Rish K Pai; Mark Jenkins; Steven Gallinger; Graham Casey; Wei Zheng; Christopher I Amos; George Davey Smith; Richard M Martin; Victor Moreno Journal: PLoS Med Date: 2022-02-03 Impact factor: 11.069
Authors: Jessica Stiles; Clarissa Amaya; Robert Pham; Rebecca K Rowntree; Mary Lacaze; Arlynn Mulne; Joyce Bischoff; Victor Kokta; Laura E Boucheron; Dianne C Mitchell; Brad A Bryan Journal: Exp Ther Med Date: 2012-08-03 Impact factor: 2.447